Pediatric tuberculosis in young children in India: a prospective study

Citation: Jain SK, Ordonez A, Kinikar A, Gupte N, Thakar M, Mave V, Jubulis J, Dharmshale S, Desai S, Hatolkar S, Kagal A, Lalvani A, Gupta A, Bharadwaj R. Pediatric tuberculosis in young children in India: a prospective study. Biomed Res Int. 2013;2013:783698. doi: 10.1155/2013/783698. Epub 2013 Dec 10. PMID: 24386640. PMCID: PMC3872373 

Access full article:

http://www.ncbi.nlm.nih.gov/pubmed/24386640

BACKGROUND:

India has one of the highest tuberculosis (TB) burdens globally. However, few studies have focused on TB in young children, a vulnerable population, where lack of early diagnosis results in poor outcomes.

METHODS:

Young children (≤ 5 years) with suspected TB were prospectively enrolled at a tertiary hospital in Pune, India. Detailed clinical evaluation, HIV testing, mycobacterial cultures, and drug susceptibility testing were performed.

RESULTS:

223 children with suspected TB were enrolled. The median age was 31 months, 46% were female, 86% had received BCG, 57% were malnourished, and 10% were HIV positive. 12% had TB disease (definite or probable), 35% did not have TB, while TB could not be ruled out in 53%. Extrapulmonary disease was noted in 46%, which was predominantly meningeal. Tuberculin skin test (TST) was positive in 20% of children with TB. Four of 7 (57%) children with culture-confirmed TB harbored drug-resistant (DR) strains of whom 2 (50%) were multi-DR (MDR). In adjusted analyses, HIV infection, positive TST, and exposure to household smoke were found to be significantly associated with children with TB (P ≤ 0.04). Mortality (at 1 year) was 3 of 26 (12%) and 1 of 79 (1%), respectively, in children with TB and those without TB (P < 0.05).

CONCLUSIONS:

Diagnosis of TB is challenging in young children, with high rates of extra-pulmonary and meningeal disease. While the data on DR-TB are limited by the small sample size, they are however concerning, and additional studies are needed to more accurately define the prevalence of DR strains in this vulnerable population.

Biomed Res Int. 2013;2013:783698. doi: 10.1155/2013/783698. Epub 2013 Dec 10. PubMed PMID: 24386640; PubMed Central PMCID: PMC3872373

Categories

CRS
Topics

Clinical Trials

A5324: A Randomized, Double-Blinded, Placebo-Controlled...

ACTG A5324 is a phase IV randomized, double-blinded, placebo-controlled study to assess the efficacy of adding Maraviroc (MVC)...

Read More

A5322: Long-Term Follow-up of Older HIV-infected Adults in...

The A5322 protocol is a long-term observational study, with a planned series of analyses of data to be collected from an...

Read More

A5225: Phase I/II Dose-Finding Study of High-Dose...

A5225/HiFLAC is a Phase I/II dose escalation and validation study of the safety, tolerability, and therapeutic effect of an...

Read More

A5321: Decay of HIV-1 Reservoirs in Patients on Long-Term...

The study is being done to try to determine which factors contribute to the persistence of HIV (how long the virus remains) in...

Read More

HPTN083: A Phase 2b/3 Double Blind Safety and Efficacy Study...

HPTN 083 is a study being done to evaluate the efficacy of the long-acting injectable agent, cabotegravir (CAB LA), for...

Read More